Novasep and PharmaZell Conclude Merger
Following exclusive negotiations that started last September, German API specialist PharmaZell and French CDMO Novasep have merged as of Apr. 7. The combined group will have revenues of nearly €500 million and employ more than 2,000 people across 10 production and R&D sites – seven in Europe, two in India and one in the US.
The companies said the merger has created a technology-driven leading CDMO and API manufacturer with the critical mass to support customers in the pharmaceutical and biotechnology sectors across the entire drug life cycle.
Sylke Hassel, former CEO of PharmaZell and CEO of the new group said: “This merger is a significant opportunity to further improve our offering, providing a broader set of technologies, a global manufacturing footprint and an end-to-end lifecycle management.”
The transaction was backed by PharmaZell’s majority shareholder Bridgepoint Group, which acquired the Raubling-based API producer in 2020.
Author: Elaine Burridge, Freelance Journalist
Bild von Alexas_Fotos auf Pixabay
